Bristol Myers Squibb announced the presentation of data at the American College of Cardiology (ACC) Annual Scientific Session and Expo, held in Atlanta, Georgia from April 6 to April 8, 2024. Data included robust safety and clinical findings of mavacamten (Camzyos) as well as compliance with the Risk Evaluation and Mitigation Strategy Program.1 “The therapeutic benefit of [mavacamten] in real-world practice, demonstrated by our data at ACC, builds on the well-established clinical program and... Read this story
